BioSpace News Archive

Soligenix, Inc. announced that Daniel P. Ring, Vice President of Business Development and Strategic Planning, will deliver a corporate presentation reviewing the Company’s two Phase 3 clinical programs and pipeline at the 25th Annual BIO-Europe International Partnering Conference in Hamburg, Germany, Tuesday, November 12, 2019 at 10:45 AM GMT.

Incremental Reimbursement in Outpatient Setting Will Expand Availability of Transformative Next-Generation Benign Prostatic Hyperplasia (BPH) Treatment

Charles River Laboratories International, Inc. reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3 million in the third quarter of 2018..

Net cash used in operating activities and purchases of property and equipment is expected to total approximately $500 million in 2019, and between $490 million and $510 million in 2020

Nephros, Inc. announced financial results for the three months ended September 30, 2019.

Meridian Bioscience, Inc. announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and live webcast on Wednesday, November 13, 2019 at 8:00 a.m.

Oncology Pharma Inc. is pleased to announce that it has entered into an agreement with Ribera for its clinical trial platform, “Connect2Med”.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2019.

Net revenue of $7.2 million in the third quarter of 2019, representing 78% growth compared to the third quarter of 2018